SELECT * FROM `stock_list` where symbol='FAB' AND exchange = 'LSE' limit 0,1
SELECT * FROM `stock_list` where symbol='FAB' AND exchange = 'LSE' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "FAB" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 Fusion Antibodies (LSE:FAB) Other Stockholders Equity
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Other Stockholders Equity

Fusion Antibodies (LSE:FAB) Other Stockholders Equity : £-0.00 Mil (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Other Stockholders Equity?

Fusion Antibodies's Other Stockholders Equity for the quarter that ended in Sep. 2023 was £-0.00 Mil.

Fusion Antibodies's quarterly Other Stockholders Equity declined from Sep. 2022 (£-0.00 Mil) to Mar. 2023 (£-0.00 Mil) but then increased from Mar. 2023 (£-0.00 Mil) to Sep. 2023 (£-0.00 Mil).

Fusion Antibodies's annual Other Stockholders Equity declined from Mar. 2021 (£0.00 Mil) to Mar. 2022 (£-0.00 Mil) and declined from Mar. 2022 (£-0.00 Mil) to Mar. 2023 (£-0.00 Mil).

Fusion Antibodies Other Stockholders Equity Historical Data

The historical data trend for Fusion Antibodies's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Other Stockholders Equity Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only - - - - -

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fusion Antibodies Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Fusion Antibodies Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Other Stockholders Equity
Comparable Companies
LSE:RENE LSE:NFX LSE:PYC LSE:GENF AQSE:INC LSE:EVG LSE:APTA LSE:IXI LSE:CIZ LSE:OCTP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Website
https://www.fusionantibodies.com
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022